DNAtrix unveils positive Phase 2 DNX-2401 study results at SNO Meeting
Category: #health  By Pankaj Singh  Date: 2019-11-25
  • share
  • Twitter
  • Facebook
  • LinkedIn

DNAtrix unveils positive Phase 2 DNX-2401 study results at SNO Meeting

 

  • The company’s drug candidate DNX-2401 in combination with Pembrolizumab depicted clinical benefit in brain tumors like Recurrent Glioblastoma.
     
  • Study data showed interim median overall survival duration of more than a year.

DNAtrix, Inc., a clinical stage, privately held biopharmaceutical firm that focuses on oncolytic virus immunotherapies to treat cancers, reportedly presented updated efficacy and safety results from its Phase 2 fully-enrolled CAPTIVE / KEYNOTE-192 DNX-2401 study during the 2019 SNO Meeting.

The study focused on assessing the efficacies of DNX-2401 (tasadenoturev), a oncolytic adenovirus developed by DNAtrix, followed by pembrolizumab in patients suffering from recurrent glioblastoma.

The outcomes showcased that the therapy evokes a durable clinical activity while also having a favorable safety profile. Positive study outcomes were presented at the 2019 SNO (Society for Neuro-Oncology) Annual Meeting that was held between November 22-24 in Phoenix, Arizona.

Overall, 48 patients suffering from recurrent glioblastoma were treated across 15 participating clinical facilities with the DNX-2401 regimen, followed by pembrolizumab. Following the treatment, a majority of the patients witnessed clinical benefits, including durable partial and complete responses.

The interim medial overall survival duration for patients is presently 12.3 months. Additionally, the interim safety analysis showcases that the treatment has a favorable benefit-risk profile. No unanticipated adverse events were recorded, and patients stayed on pembrolizumab for over 5.5 months with 34 cycles.

Presenting author of the Phase 2 study, Clark Chen, MD, PhD, stated that the positive data possesses great promise for individuals affected by glioblastoma, a commonly occurring adult brain cancer form. The disease is associated with uniform fatality and the outcomes are striking in that context.

Dr. Chen further added, the data suggests that the DNX-2401 and pembrolizumab combination could potentially revolutionize glioblastoma patient care. The company looks forward to conducting thorough studies that are focused at validating the overall efficacy of DNX-2401.

The CEO of DNAtrix, Frank Tufaro, PhD, stated that the interim data from the company’s CAPTIVE study is a significant milestone for DNAtrix to develop DNX-2401 as a novel, innovative glioblastoma treatment.

Source credit: https://www.dnatrix.com/view.cfm/123/2019-press-release

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Roche announces new data from Phase 3 FeDeriCa trial for breast cancer
Roche announces new data from Phase 3 FeDeriCa trial for breast cancer
By Pankaj Singh

Roche Holding, a renowned Swiss healthcare company working in pharmaceuticals and diagnostics, reportedly announced novel data from its Phase 3 FeDeriCa trial. The trial showed the investigational FDC (fixed-dose combination) of pertuzumab (Perjeta&r...

Genentech announces updated data from Venclexta® clinical trials
Genentech announces updated data from Venclexta® clinical trials
By Pankaj Singh

Chronic lymphocytic leukemia (CLL) is a common type of adult leukemia. In the United States, it is estimated that more than 20,000 new cases of CLL will be diagnosed in 2019. With an eye to cure CLL, biotechnology company Genentech, Inc. has recently...

CoSara receives Indian regulatory authorization for its five IVDs
CoSara receives Indian regulatory authorization for its five IVDs
By Pankaj Singh

Co-Diagnostics, a renowned US-based molecular diagnostics company, having a patented, unique platform to develop diagnostics tests reportedly announced that CoSara Diagnostics, the company’s JV for production, has received regulatory clearance ...